T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$3.3B |
| 2 |
Eli Lilly
LLY
|
+$2.75B |
| 3 |
AstraZeneca
AZN
|
+$1.98B |
| 4 |
Coupang
CPNG
|
+$1.54B |
| 5 |
Fortinet
FTNT
|
+$1.48B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NXP Semiconductors
NXPI
|
+$2.34B |
| 2 |
Morgan Stanley
MS
|
+$2.26B |
| 3 |
Airbnb
ABNB
|
+$2.04B |
| 4 |
Qualcomm
QCOM
|
+$1.95B |
| 5 |
NVIDIA
NVDA
|
+$1.81B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.35% |
| 2 | Healthcare | 16.19% |
| 3 | Consumer Discretionary | 15.55% |
| 4 | Financials | 12.84% |
| 5 | Communication Services | 12.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGRX
2701
DELISTED
Agile Therapeutics
AGRX
| $182K | ﹤0.01% |
44
+21
| +91% | +$114K |
|
2702
Gogo Inc
GOGO
$383M
| $181K | ﹤0.01% |
18,737
-32,570
| -63% | -$387K |
|
|
SBEAU
2703
DELISTED
SilverBox Engaged Merger Corp I Units
SBEAU
| $179K | ﹤0.01% |
+18,100
| New | +$181K |
|
2704
Matinas BioPharma
MTNB
$1.52M
| $178K | ﹤0.01% |
+3,396
| New | +$228K |
|
|
VELOU
2705
DELISTED
Velocity Acquisition Corp. Units
VELOU
| $178K | ﹤0.01% |
+18,100
| New | +$181K |
|
2706
MediciNova
MNOV
$64.5M
| $175K | ﹤0.01% |
+34,587
| New | +$201K |
|
2707
Northern Oil and Gas
NOG
$2.57B
| $174K | ﹤0.01% |
14,370
| – | – |
|
2708
Talphera
TLPH
$62.8M
| $173K | ﹤0.01% |
+5,086
| New | +$202K |
|
2709
Minerva Neurosciences
NERV
$192M
| $172K | ﹤0.01% |
+7,376
| New | +$184K |
|
|
NAGE
2710
Niagen Bioscience
NAGE
$239M
| $171K | ﹤0.01% |
18,278
-9,916
| -35% | -$78.6K |
|
|
PRMW
2711
DELISTED
Primo Water Corporation
PRMW
| $171K | ﹤0.01% |
10,523
-25
| -0.2% | -$402 |
|
2712
Wave Life Sciences
WVE
$1.04B
| $170K | ﹤0.01% |
30,288
-736,108
| -96% | -$7.07M |
|
2713
Primis Financial Corp
FRST
$414M
| $168K | ﹤0.01% |
11,566
-87
| -0.7% | -$1.2K |
|
2714
CorMedix
CRMD
$613M
| $166K | ﹤0.01% |
+16,615
| New | +$175K |
|
2715
Lufax Holding
LU
$1.31B
| $166K | ﹤0.01% |
2,850
-3,900
| -58% | -$240K |
|
|
BCEL
2716
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $166K | ﹤0.01% |
10,817
+74
| +0.7% | +$1.2K |
|
|
FLXN
2717
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $166K | ﹤0.01% |
+18,551
| New | +$213K |
|
|
SHSP
2718
DELISTED
SharpSpring, Inc.
SHSP
| $166K | ﹤0.01% |
+10,400
| New | +$207K |
|
|
FSP
2719
Franklin Street Properties
FSP
$46.6M
| $161K | ﹤0.01% |
29,581
-22,876
| -44% | -$114K |
|
|
BHR
2720
Braemar Hotels & Resorts
BHR
$140M
| $160K | ﹤0.01% |
26,318
-10,170
| -28% | -$59.7K |
|
2721
Genprex
GNPX
$2.54M
| $160K | ﹤0.01% |
1
| – | – |
|
|
CEMI
2722
DELISTED
Chembio diagnostics, Inc.
CEMI
| $158K | ﹤0.01% |
45,124
+6,521
| +17% | +$36.3K |
|
2723
Genie Energy
GNE
$385M
| $157K | ﹤0.01% |
24,801
-36
| -0.1% | -$270 |
|
|
CNR
2724
Core Natural Resources Inc
CNR
$4.61B
| $154K | ﹤0.01% |
15,882
-20,491
| -56% | -$200K |
|
2725
Curis
CRIS
$3.39M
| $152K | ﹤0.01% |
34
-5
| -13% | -$20.9K |
|
Similar funds
T. Rowe Price Associates's Q1 2021 Portfolio in Review
As of Q1 2021, T. Rowe Price Associates held 2,908 positions worth $999B, up 2.5% from $974B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
T. Rowe Price Associates's Q1 2021 filing shows 248 new, 1,171 increased, 1,334 reduced and 66 closed positions. Its largest new stake was Coupang: 33,380,859 shares worth $1.63B. The largest sale was NXP Semiconductors, an estimated $2.34B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2021 buy was Coupang: 33,380,859 shares worth $1.63B.
- T. Rowe Price Associates added most to Zoom in Q1 2021, an estimated $3.3B increase.
- T. Rowe Price Associates's biggest Q1 2021 reduction was NXP Semiconductors, cutting an estimated $2.34B.
- T. Rowe Price Associates fully exited CONCHO RESOURCES INC. in Q1 2021, selling an estimated $205M.
- T. Rowe Price Associates's ten largest holdings make up 24% of its $999B portfolio in Q1 2021.
- T. Rowe Price Associates opened 248 new positions and closed 66 in Q1 2021.
- T. Rowe Price Associates's portfolio value rose 2.5% quarter-over-quarter to $999B.
Based on T. Rowe Price Associates's 13F filing for Q1 2021, filed 17 May 2021.